{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:26Z","timestamp":1786119926072,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8,15]]},"DOI":"10.1097\/tp.0b013e318223d7f3","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T02:32:41Z","timestamp":1308623561000},"page":"321-327","source":"Crossref","is-referenced-by-count":10,"title":["Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients"],"prefix":"10.1097","volume":"92","author":[{"given":"Klemens","family":"Budde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio","family":"Tedesco-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Arns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shoker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prestele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soniya","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00007890-200003150-00035","article-title":"Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506\/MMF Dose-Ranging Kidney Transplant Study Group.","volume":"69","author":"Miller","year":"2000","journal-title":"Transplantation"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0272-6386(99)70358-6","article-title":"US Renal Transplant Mycophenolate Mofetil Study Group.","volume":"34","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/TP.0b013e3181b0e65e","article-title":"Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.","volume":"88","author":"Cooper","year":"2009","journal-title":"Transplantation"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","article-title":"Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study.","volume":"4","author":"Budde","year":"2004","journal-title":"Am J Transplant"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil.","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2004.00455.x","article-title":"Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation.","volume":"4","author":"Kiberd","year":"2004","journal-title":"Am J Transplant"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":"A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2125.2009.03612.x","article-title":"Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: Limited sampling strategies and clinical outcome in renal transplant patients.","volume":"69","author":"Sommerer","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trre.2008.05.003","article-title":"Immunosuppression in renal transplantation: Some aspects for the modern era.","volume":"22","author":"Chadban","year":"2008","journal-title":"Transplant Rev (Orlando)"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial.","volume":"86","author":"van Gelder","year":"2008","journal-title":"Transplantation"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2215\/CJN.06050809","article-title":"Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.","volume":"5","author":"Glander","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.ftd.0000158083.45954.97","article-title":"Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: A computer simulation.","volume":"27","author":"van Hest","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e31820d3b9b","article-title":"Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients.","volume":"91","author":"Sommerer","year":"2011","journal-title":"Transplantation"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1097\/01.tp.0000186380.61251.fc","article-title":"The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation.","volume":"80","author":"van Gelder","year":"2005","journal-title":"Transplantation"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.09091209","article-title":"The CLEAR Study: A 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.","volume":"5","author":"Gourishankar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-12-20210129","first-page":"66","article-title":"The association of early sub-therapeutic MPA exposure (<30 mg.h\/l) and acute rejection: A cohort analysis of the CLEAR study.","volume":"22","author":"Kiberd","year":"2009","journal-title":"Transplant International"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS \u2014A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease.","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1008841022998","article-title":"Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.","volume":"7","author":"Revicki","year":"1998","journal-title":"Qual Life Res"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","article-title":"Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management.","volume":"24","author":"Behrend","year":"2001","journal-title":"Drug Saf"},{"key":"R23-12-20210129","first-page":"321","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection.","volume":"45","year":"1995","journal-title":"Lancet"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","article-title":"Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.","volume":"4","author":"Salvadori","year":"2004","journal-title":"Am J Transplant"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":"The Banff 97 working classification of renal allograft pathology.","volume":"55","author":"Racusen","year":"1999","journal-title":"Kidney Int"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/j.1600-6143.2004.00585.x","article-title":"Banff 2003 meeting report: New diagnostic insights and standards.","volume":"4","author":"Racusen","year":"2004","journal-title":"Am J Transplant"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jchromb.2004.10.004","article-title":"Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry.","volume":"813","author":"Patel","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/clinchem\/46.3.365","article-title":"Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit.","volume":"46","author":"Shipkova","year":"2000","journal-title":"Clin Chem"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-201108150-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:29:02Z","timestamp":1786044542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201108150-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,15]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e318223d7f3","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,15]]}}}